Bern, Switzerland
Bern, Switzerland

Time filter

Source Type

News Article | April 24, 2017
Site: www.eurekalert.org

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis. When the liver fails to compensate for the functional overload resulting from disease, a situation called decompensation occurs. Decompensation significantly lowers the survival rate among patients with cirrhosis, and very few effective drugs are available. This latest study assessed information on 1350 cirrhotic patients identified from a representative group of Taiwan National Health Insurance beneficiaries from 2000 to 2013. Statin use was linked with a decreased the risk of decompensation in a dose-dependent manner. "The study demonstrates a favorable outcome that should be re-confirmed by future prospective and large-scaled studies," said senior author Dr. Ching-Liang Lu. "Moreover, future investigations should also explore whether the favorable effect of statin use can also be extended to cirrhosis due to other causes, such as alcohol."


1. Hudson. M. et al. Rifaximin-α is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study. Abstracto ILC2017-RS-1526. The International Liver Congress, del 19 al 23 de abril de 2017; Ámsterdam, Países Bajos. 2. Aspinall R. et al. The impact of rifaximin-alpha on NHS hospital resource use in UK patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Abstracto ILC2016-RS-1132. The International Liver Congress, del 13 al 17 de abril de 2016 3. Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014. 109. 1757-63. 4. Fleming K M. et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: A general population-based study. Journal of Hepatology 49 (2008) 732-738.


1. Hudson. M. et al. Rifaximin-α is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study (Rifaximin-α bewirkt eine Reduktion der in der Notaufnahme notwendigen Einsatzmittel für Patienten mit hepatitischer Enzephalopathie in Großbritannien: praxisbezogener Nachweis laut IMPRESS-Studie). Auszug ILC2017-RS-1526. The International Liver Congress, 19.-23. April 2017; Amsterdam, Niederlande. 2. Aspinall R. et al. The impact of rifaximin-alpha on NHS hospital resource use in UK patients with hepatic encephalopathy: a retrospective observational study (IMPRESS) [Die Auswirkung von Rifaximin-α auf in Gesundheitsdiensten/Krankenhäusern verwendete Einsatzmittel für Patienten mit hepatitischer Enzephalopathie: eine retrospektive Beobachtungsstudie (IMPRESS)]. Auszug ILC2016-RS-1132. The International Liver Congress, 13.-17. April 2016 3. Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization (Die Überlebenschancen mit einer latenten hepatitischen Enzephalopathie sind gering und ein potenzieller Krankenhausaufenthalt ist wahrscheinlich). Am J Gastroenterol. 2014. 109. 1757-63. 4. Fleming K M. et al. Incidence and prevalence of cirrhosis in the United Kingdom (Häufigkeit und Verbreitung der Zirrhose in Großbritannien), 1992-2001: A general population-based study (Allgemeine bevölkerungsbezogene Studie). Journal of Hepatology 49 (2008) 732-738.


- Lancement du nouveau passeport patient permettant de gérer la maladie et les interactions avec l'équipe soignante Norgine et l'ELPA ont lancé aujourd'hui un dépliant destiné au patient dont l'objectif est d'améliorer la détection précoce de l'encéphalopathie hépatique, ainsi qu'un passeport patient permettant de faciliter les conversations avec les professionnels de santé. L'encéphalopathie hépatique reste insuffisamment diagnostiquée et traitée, car de nombreux patients et soignants ignorent les signes et les symptômes de cette maladie. En outre, les prestataires de soins de santé n'identifient et ne traitent pas toujours les symptômes souvent subtiles de l'encéphalopathie hépatique, ce qui peut entraîner des résultats médiocres pour les patients et une augmentation des hospitalisations.[1] Pour consulter la version multimédia de ce communiqué de presse, veuillez cliquer ici : L'encéphalopathie hépatique est une complication importante d'une maladie chronique du foie à un stade avancé, et survient chez 40 % des patients au maximum, soit jusqu'à 200 000* personnes en Europe.[1],[2] Tatjana Reic, présidente de l'ELPA, a déclaré : « En Europe, 200 000 personnes sont touchées par l'encéphalopathie hépatique, et malgré la gravité de la maladie, celle-ci continue d'être insuffisamment diagnostiquée et traitée. Les nouveaux dépliant et passeport destinés au patient sont les bienvenus, car ils vont aider les patients et leurs soignants à gérer cette maladie débilitante qui peut avoir un impact important sur la vie des personnes et de leurs proches. » Selon Peter Martin, Chief Operating Officer chez Norgine : « Norgine est fortement déterminée à travailler avec l'ELPA afin qu'ensemble, nous puissions nous assurer que l'encéphalopathie hépatique soit reconnue comme une maladie potentiellement mortelle et que la gestion des patients puisse se faire en conséquence. » Cliquez ici pour télécharger le dépliant destiné au patient Understanding Hepatic Encephalopathy (Comprendre l'encéphalopathie hépatique) Cliquez ici pour télécharger le passeport patient Le dépliant destiné au patient Understanding Hepatic Encephalopathy (Comprendre l'encéphalopathie hépatique), le passeport patient et le rapport Time to DeLiver sont sponsorisés par Norgine. Consultez le communiqué de presse dans son intégralité sur http://www.norgine.com *En supposant que la population européenne soit de 500 000 personnes 1. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology 2014 ; 61(3):642-659 2. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther. Février 2007 ; 25 Suppl 1:11-6.


- Lancement du nouveau passeport patient permettant de gérer la maladie et les interactions avec l'équipe soignante Norgine et l'ELPA ont lancé aujourd'hui un dépliant destiné au patient dont l'objectif est d'améliorer la détection précoce de l'encéphalopathie hépatique, ainsi qu'un passeport patient permettant de faciliter les conversations avec les professionnels de santé. L'encéphalopathie hépatique reste insuffisamment diagnostiquée et traitée, car de nombreux patients et soignants ignorent les signes et les symptômes de cette maladie. En outre, les prestataires de soins de santé n'identifient et ne traitent pas toujours les symptômes souvent subtiles de l'encéphalopathie hépatique, ce qui peut entraîner des résultats médiocres pour les patients et une augmentation des hospitalisations.[1] Pour consulter la version multimédia de ce communiqué de presse, veuillez cliquer ici : L'encéphalopathie hépatique est une complication importante d'une maladie chronique du foie à un stade avancé, et survient chez 40 % des patients au maximum, soit jusqu'à 200 000* personnes en Europe.[1],[2] Tatjana Reic, présidente de l'ELPA, a déclaré : « En Europe, 200 000 personnes sont touchées par l'encéphalopathie hépatique, et malgré la gravité de la maladie, celle-ci continue d'être insuffisamment diagnostiquée et traitée. Les nouveaux dépliant et passeport destinés au patient sont les bienvenus, car ils vont aider les patients et leurs soignants à gérer cette maladie débilitante qui peut avoir un impact important sur la vie des personnes et de leurs proches. » Selon Peter Martin, Chief Operating Officer chez Norgine : « Norgine est fortement déterminée à travailler avec l'ELPA afin qu'ensemble, nous puissions nous assurer que l'encéphalopathie hépatique soit reconnue comme une maladie potentiellement mortelle et que la gestion des patients puisse se faire en conséquence. » Cliquez ici pour télécharger le dépliant destiné au patient Understanding Hepatic Encephalopathy (Comprendre l'encéphalopathie hépatique) Cliquez ici pour télécharger le passeport patient Le dépliant destiné au patient Understanding Hepatic Encephalopathy (Comprendre l'encéphalopathie hépatique), le passeport patient et le rapport Time to DeLiver sont sponsorisés par Norgine. Consultez le communiqué de presse dans son intégralité sur http://www.norgine.com *En supposant que la population européenne soit de 500 000 personnes 1. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology 2014 ; 61(3):642-659 2. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther. Février 2007 ; 25 Suppl 1:11-6.


The global HLA typing transplant market to grow at a CAGR of 9.20% during the period 2017-2021. The report, Global HLA Typing Transplant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. One trend in the market is new government initiatives for HLA typing. The growing concerns about hepatitis and HIV are leading the government to develop few standards and strategies to reduce the number of communicable diseases through transplantation. Quality measurement in government-introduced programs lead to increased adoption of bone marrow and umbilical cord transplantation. According to the report, one driver in the market is growing incidence of organ failure. The demand for tissue and organs such as bone marrow, heart, liver, kidney, and lungs is very high worldwide. The increasing rate of alcohol consumption, unhealthy lifestyles and food habits, and drug intake are the leading causes of organ failure. In addition, the rise in older adult population results in increased demand for organs for transplantation. According to a combined study conducted by the Department of Internal Medicine, Division of Hepatology, Loyola University Medical Center; Department of Preventive Health Sciences, Stritch School of Medicine, Loyola University Chicago; and Division of Gastroenterology and Hepatology, University of Michigan Health System, in 2015, liver cirrhosis is one of the major factors of death in the US. PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: Market landscape PART 06: Market segmentation by products PART 07: Market segmentation by technology PART 08: Market segmentation by end-user PART 09: Geographical segmentation PART 10: Decision framework PART 11: Drivers and challenges PART 12: Market trends PART 13: Vendor landscape PART 14: Key vendor analysis PART 15: Appendix For more information about this report visit http://www.researchandmarkets.com/research/4zmjxq/global_hla_typing To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-hla-typing-transplant-market-to-grow-at-a-cagr-of-92-by-2021-growth-driven-by-new-government-initiatives-for-hla-typing---research-and-markets-300451293.html


News Article | May 4, 2017
Site: www.eurekalert.org

Biologists from UNIGE have discovered how this organ adapts to the cycles of feeding and fasting, and the alternation of day and night In mammals, the liver plays a pivotal role in metabolism and the elimination of toxins, and reaches its maximum efficiency when they are active and feed. Biologists from the University of Geneva (UNIGE), Switzerland, have discovered how this organ adapts to the cycles of feeding and fasting, and the alternation of day and night within 24 hours. The researchers showed in mice that the size of the liver increases by almost half before returning to its initial dimensions, according to the phases of activity and rest. Published in the journal Cell, their study describes the cellular mechanisms of this fluctuation, which disappears when the normal biological rhythm is reversed. The disruption of our circadian clock due to professional constraints or private habits therefore probably has important repercussions on our liver functions. Mammals have adapted to diurnal and nocturnal rhythms using a central clock located in the brain. The latter, which is resettled every day by the light, synchronizes the subordinate clocks present in most of our cells. In the liver, more than 350 genes involved in metabolism and detoxification are expressed in a circadian fashion, with a biological rhythm of 24 hours. "Many of them are also influenced by the rhythm of food intake and physical activity, and we wanted to understand how the liver adapts to these fluctuations", says Ueli Schibler, professor emeritus at the Department of Molecular Biology of the UNIGE Faculty of Science. The liver oscillates, but not the other organs The mice forage and feed at night, while the day is spent resting. "In rodents following a usual circadian rhythm, we observed that the liver gradually increases during the active phase to reach a peak of more than 40% at the end of the night, and that it returns to its initial size during the day", notes Flore Sinturel, researcher of the Geneva group and first author of the study. The cellular mechanisms of this adaptation were discovered in collaboration with scientists from the Nestlé Institute of Health Sciences (NIHS) and the University of Lausanne (UNIL) in Switzerland. Researchers have shown that the size of liver cells and their protein content oscillate in a daily manner. The number of ribosomes, the organelles responsible for producing the proteins required for the various functions of the liver, fluctuates together with the size of the cell. "The latter adapts the production and assembly of new ribosomes to ensure a peak of protein production during the night. The components of ribosomes produced in excess are then identified, labeled, and degraded during the resting phase", explains Flore Sinturel. The amplitude of the variations observed by the biologists depends on the cycles of feeding and fasting, as well as diurnal and nocturnal phases. Indeed, the fluctuations disappear when the phases of feeding no longer correspond to the biological clock, which evolved in the course of hundreds of millions of years: "the size of the liver and the hepatocytes, as well as their contents in ribosomes and proteins, remain nearly stable when mice are fed during the day. Yet, these animals ingest similar amounts of food, irrespective of whether they are fed during the night or during the day", points out Frédéric Gachon of the NIHS, who co-directed the study. Many human subjects no longer live according to the rhythm of their circadian clock, due to night work hours, alternating schedules or frequent international travels. A previous study (Leung et al., Journal of Hepatology, 1986) determining the volume of the human liver during six hours using methods based on ultrasound, suggests that this organ also oscillates within us. If mechanisms similar to those found in mice exist in humans, which is likely to be the case, the deregulation of our biological rhythms would have a considerable influence on hepatic functions.


1. Hudson. M. et al. Rifaximin-α is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study. (La rifaximine-α est associée à des réductions de l'usage des ressources des services d'urgence chez les patients britanniques atteints d'encéphalopathie hépatique : données concrètes de l'étude IMPRESS.) Abstract ILC2017-RS-1526. The International Liver Congress, 19-23 avril 2017 ; Amsterdam, Pays-Bas. 2. Aspinall R. et al. The impact of rifaximin-alpha on NHS hospital resource use in UK patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). (L'impact de la rifaximine-alpha sur l'usage des ressources des hôpitaux du NHS chez les patients britanniques atteints d'encéphalopathie hépatique : une étude d'observation rétrospective [IMPRESS].) Abstract ILC2016-RS-1132. The International Liver Congress, 13-17 avril 2016. 3. Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. (L'encéphalopathie hépatique masquée est indépendamment associée à un faible taux de survie et un risque d'hospitalisation accru.) Am J Gastroenterol. 2014. 109. 1757-63. 4. Fleming K M. et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: A general population-based study. (Incidence et prévalence de la cirrhose au Royaume-Uni, 1992-2001 : une étude basée sur l'ensemble de la population.) Journal of Hepatology 49 (2008) 732-738.


This data was sponsored by Norgine and presented at The International Liver Congress on 19-23 April 2017, The Netherlands. IMPRESS is a retrospective observational study that included 11 specialist National Health Service (NHS) centres with 145 patients prescribed rifaximin-α for hepatic encephalopathy. In the study, treatment with rifaximin-α for hepatic encephalopathy was well tolerated.[2] Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease.[3] Hepatic encephalopathy affects around 10,000 patients in the UK.[4] Peter Martin, Chief Operating Officer at Norgine said, "The IMPRESS study continues to reinforce the value of rifaximin-α in reducing the recurrence of episodes of hepatic encephalopathy. By recognising hepatic encephalopathy patients and treating them as early as possible with rifaximin-α, healthcare systems will make significant savings." XIFAXAN® 550mg / TARGAXAN® 550mg / TIXTELLER® 550mg (rifaximin-α) is reimbursed through healthcare systems in Australia, England and Wales, Germany, Ireland, Italy, Luxembourg, Netherlands, New Zealand, Norway, Scotland, Sweden and Switzerland. Norgine currently holds marketing rights for XIFAXAN® 550mg (known as TARGAXAN® 550mg in the UK and Belgium) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden and United Kingdom. 1. Hudson. M. et al. Rifaximin-α is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study. Abstract ILC2017-RS-1526. The International Liver Congress, 19-23 April 2017; Amsterdam, The Netherlands. 2. Aspinall R. et al. The impact of rifaximin-alpha on NHS hospital resource use in UK patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Abstract ILC2016-RS-1132. The International Liver Congress, 13-17 April 2016 3. Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014. 109. 1757-63. 4. Fleming K M. et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: A general population-based study. Journal of Hepatology 49 (2008) 732-738.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global HLA Typing Transplant Market 2017-2021" report to their offering. The global HLA typing transplant market to grow at a CAGR of 9.20% during the period 2017-2021. The report, Global HLA Typing Transplant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. One trend in the market is new government initiatives for HLA typing. The growing concerns about hepatitis and HIV are leading the government to develop few standards and strategies to reduce the number of communicable diseases through transplantation. Quality measurement in government-introduced programs lead to increased adoption of bone marrow and umbilical cord transplantation. According to the report, one driver in the market is growing incidence of organ failure. The demand for tissue and organs such as bone marrow, heart, liver, kidney, and lungs is very high worldwide. The increasing rate of alcohol consumption, unhealthy lifestyles and food habits, and drug intake are the leading causes of organ failure. In addition, the rise in older adult population results in increased demand for organs for transplantation. According to a combined study conducted by the Department of Internal Medicine, Division of Hepatology, Loyola University Medical Center; Department of Preventive Health Sciences, Stritch School of Medicine, Loyola University Chicago; and Division of Gastroenterology and Hepatology, University of Michigan Health System, in 2015, liver cirrhosis is one of the major factors of death in the US. For more information about this report visit http://www.researchandmarkets.com/research/3rgnwf/global_hla_typing

Loading Hepatology collaborators
Loading Hepatology collaborators